Tezepelumab in patients with allergic and eosinophilic asthma.
allergic asthma
eosinophilic asthma
tezepelumab
thymic stromal lymphopoietin
Journal
Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028
Informations de publication
Date de publication:
26 Dec 2023
26 Dec 2023
Historique:
revised:
05
12
2023
received:
11
08
2023
accepted:
10
12
2023
medline:
26
12
2023
pubmed:
26
12
2023
entrez:
26
12
2023
Statut:
aheadofprint
Résumé
Asthma is a heterogeneous disease commonly driven by allergic and/or eosinophilic inflammation, both of which may be present in severe disease. Most approved biologics for severe asthma are indicated for specific phenotypes and target individual downstream type 2 components of the inflammatory cascade. Tezepelumab, a human monoclonal antibody (immunoglobulin G2λ), binds specifically to thymic stromal lymphopoietin (TSLP), an epithelial cytokine that initiates and sustains allergic and eosinophilic inflammation in asthma. By blocking TSLP, tezepelumab has demonstrated efficacy across known asthma phenotypes and acts upstream of all current clinically used biomarkers. In a pooled analysis of the phase 2b PATHWAY (NCT02054130) and phase 3 NAVIGATOR (NCT03347279) studies, compared with placebo, tezepelumab reduced the annualized asthma exacerbation rate over 52 weeks by 62% (95% confidence interval [CI]: 53, 70) in patients with perennial aeroallergen sensitization (allergic asthma); by 71% (95% CI: 62, 78) in patients with a baseline blood eosinophil count ≥300 cells/μL; and by 71% (95% CI: 59, 79) in patients with allergic asthma and a baseline blood eosinophil count ≥300 cells/μL. This review examines the efficacy and mode of action of tezepelumab in patients with allergic asthma, eosinophilic asthma and coexisting allergic and eosinophilic phenotypes.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : AstraZeneca
Organisme : Amgen
Informations de copyright
© 2023 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Références
Chen M, Shepard K 2nd, Yang M, et al. Overlap of allergic, eosinophilic and type 2 inflammatory subtypes in moderate-to-severe asthma. Clin Exp Allergy. 2021;51(4):546-555.
Wenzel SE. Severe adult asthmas: integrating clinical features, biology, and therapeutics to improve outcomes. Am J Respir Crit Care Med. 2021;203(7):809-821.
Csoma Z, Gál Z, Gézsi A, Herjavecz I, Szalai C. Prevalence and characterization of severe asthma in Hungary. Sci Rep. 2020;10(1):9274.
Tran TN, Zeiger RS, Peters SP, et al. Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthma. Ann Allergy Asthma Immunol. 2016;116(1):37-42.
Domingo C, Sicras-Mainar A, Sicras-Navarro A, Sogo A, Mirapeix RM, Engroba C. Prevalence, T2-biomarkers and cost of severe asthma in the era of biologics: the BRAVO-1 study. J Investig Allergol Clin Immunol. 2022;34. doi:10.18176/jiaci.0871
Backman H, Räisänen P, Hedman L, et al. Increased prevalence of allergic asthma from 1996 to 2006 and further to 2016-results from three population surveys. Clin Exp Allergy. 2017;47(11):1426-1435.
US Food and Drug Administration. XOLAIR® (omalizumab) Prescribing Information. 2021 Accessed May 15, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/omalgen062003LB.pdf
Vaillant AA, Vashisht R, Zito PM. Immediate hypersensitivity reactions. 2023 Accessed July 6, 2023. https://www.ncbi.nlm.nih.gov/books/NBK513315/
Global Initiative for Asthma. Global strategy for asthma management and prevention. 2022 Accessed November 8, 2022. https://ginasthma.org/wp-content/uploads/2022/07/GINA-Main-Report-2022-FINAL-22-07-01-WMS.pdf
US Food and Drug Administration. FASENRA™ (benralizumab) Prescribing Information. 2017 Accessed May 15, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761070s000lbl.pdf
US Food and Drug Administration. NUCALA® (mepolizumab) Prescribing Information. 2015 Accessed May 15, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125526Orig1s000Lbl.pdf
Global Initiative for Asthma. Global strategy for asthma management and prevention. 2020 Accessed July 26, 2021. https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-final-_wms.pdf
Heaney LG, Perez de Llano L, Al-Ahmad M, et al. Eosinophilic and noneosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort. Chest. 2021;160(3):814-830.
Oppenheimer J, Hoyte FCL, Phipatanakul W, Silver J, Howarth P, Lugogo NL. Allergic and eosinophilic asthma in the era of biomarkers and biologics: similarities, differences and misconceptions. Ann Allergy Asthma Immunol. 2022;129(2):169-180.
Hanania NA, Wenzel S, Rosén K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187(8):804-811.
Albers FC, Mullerova H, Gunsoy NB, et al. Biologic treatment eligibility for real-world patients with severe asthma: the IDEAL study. J Asthma. 2018;55(2):152-160.
Lommatzsch M, Julius P, Kuepper M, et al. The course of allergen-induced leukocyte infiltration in human and experimental asthma. J Allergy Clin Immunol. 2006;118(1):91-97.
Carr TF, Zeki AA, Kraft M. Eosinophilic and noneosinophilic asthma. Am J Respir Crit Care Med. 2018;197(1):22-37.
Ricciardolo FLM, Guida G, Bertolini F, Di Stefano A, Carriero V. Phenotype overlap in the natural history of asthma. Eur Respir Rev. 2023;32(168):220201.
US Food and Drug Administration. CINQAIR® (reslizumab) Prescribing Information. 2016 Accessed May 15, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761033lbl.pdf
US Food and Drug Administration. Dupixent® (dupilumab) Prescribing Information. 2017 Accessed May 15, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761055lbl.pdf
Corren J, Castro M, O'Riordan T, et al. Dupilumab efficacy in patients with uncontrolled, moderate-to-severe allergic asthma. J Allergy Clin Immunol Pract. 2020;8(2):516-526.
Menzies-Gow A, Steenkamp J, Singh S, et al. Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison. J Med Econ. 2022;25(1):679-690.
Prazma CM, Idzko M, Douglass JA, et al. Response to mepolizumab treatment in patients with severe eosinophilic asthma and atopic phenotypes. J Asthma Allergy. 2021;14:675-683.
Casale TB, Chipps BE, Rosen K, et al. Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma. Allergy. 2018;73(2):490-497.
Menzies-Gow A, Wechsler ME, Brightling CE, et al. Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study. Lancet Respir Med. 2023;11:425-438.
Corren J, Parnes J, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936-946.
Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809.
Corren J, Ambrose CS, Griffiths JM, et al. Efficacy of tezepelumab in patients with evidence of severe allergic asthma: results from the phase 3 NAVIGATOR study. Clin Exp Allergy. 2022;53:417-428.
Gauvreau GM, Sehmi R, Ambrose CS, Griffiths JM. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777-792.
Domingo C, Mirapeix RM. From the allergic cascade to the epithelium-driven disease: the long road of bronchial asthma. Int J Mol Sci. 2023;24(3):2716.
Diver S, Khalfaoui L, Emson C, et al. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9(11):1299-1312.
Corren J, Pham TH, Garcia Gil E, et al. Baseline type 2 biomarker levels and response to tezepelumab in severe asthma. Allergy. 2022;77(6):1786-1796.
Sverrild A, Hansen S, Hvidtfeldt M, et al. The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM). Eur Respir J. 2022;59(1):2101296.
Gauvreau GM, O'Byrne PM, Boulet LP, et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med. 2014;370(22):2102-2110.
Soumelis V, Reche PA, Kanzler H, et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol. 2002;3(7):673-680.
Ito T, Wang YH, Duramad O, et al. TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J Exp Med. 2005;202(9):1213-1223.
Lambrecht BN, Hammad H, Fahy JV. The cytokines of asthma. Immunity. 2019;50(4):975-991.
Allakhverdi Z, Comeau MR, Jessup HK, et al. Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells. J Exp Med. 2007;204(2):253-258.
Nagarkar DR, Poposki JA, Comeau MR, et al. Airway epithelial cells activate Th2 cytokine production in mast cells through IL-1 and thymic stromal lymphopoietin. J Allergy Clin Immunol. 2012;130(1):225-232 e4.
Salter BM, Oliveria JP, Nusca G, et al. Thymic stromal lymphopoietin activation of basophils in patients with allergic asthma is IL-3 dependent. J Allergy Clin Immunol. 2015;136(6):1636-1644.
Caminati M, Llanos JP, Spahn JD, et al. Changes in serum total IgE after cessation of tezepelumab after 2 years of treatment (DESTINATION). Eur Respiratory J. 2023;62:OA1419.
Corren J, Larson D, Altman MC, et al. Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: a randomized controlled trial. J Allergy Clin Immunol. 2023;151(1):192-201.
Gauvreau GM, Hohlfeld JM, FitzGerald JM, et al. Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma. Eur Respir J. 2023;61(3):2201193.
Corren J, Ambrose CS, Salapa K, et al. Efficacy of tezepelumab in patients with severe, uncontrolled asthma and perennial allergy. J Allergy Clin Immunol Pract. 2021;9:4334-4342.e6.
Corren J, Menzies-Gow A, Chupp G, et al. Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of PATHWAY and NAVIGATOR studies. Am J Respir Crit Care Med. 2023;208(1):13-24.
Carr TBJ, Cook B, Hunter G, et al. Efficacy of Tezepelumab in patients with severe, uncontrolled asthma with respiratory comorbidities: results from the phase 3 NAVIGATOR study. J Allergy Clin Immunol. 2022;149(2 Suppl):AB152.
Bourdin A, Corren J, Ambrose C, et al. Efficacy of tezepelumab in patients with perennial allergic asthma: results from the NAVIGATOR Phase 3 Study. 2021 76 (S110):586-587.
Lindsley A, Colice G, Martin N, et al. Efficacy of tezepelumab in patients with severe, uncontrolled asthma by specific perennial allergen immunoglobulin E thresholds. J Allergy Clin Immunol. 2023;151:AB18.
Hoyte F, Martin N, Kmita K, et al. Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma: results from the phase 3 NAVIGATOR study. J Allergy Clin Immunol. 2022;149:AB63.
Brusselle G, Spahn JD, Hunter G, Martin N, Llanos-Ackert J-P, Ponnasrambil S. Efficacy of tezepelumab according to age at asthma onset in NAVIGATOR. Eur Respir J. 2022;60:1835.
Hanania NA, Alpan O, Hamilos DL, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011;154(9):573-582.
Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;(1):Cd003559.
Tepper RS, Wise RS, Covar R, et al. Asthma outcomes: pulmonary physiology. J Allergy Clin Immunol. 2012;129(3 Suppl):S65-S87.
Juniper EF, O’Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999;14:902-907.
Juniper EF, Buist AS, Cox FM, Ferrie PJ, King DR. Validation of a standardized version of the asthma quality of life questionnaire. Chest. 1999;115(5):1265-1270.
Bartemes KR, Kephart GM, Fox SJ, Kita H. Enhanced innate type 2 immune response in peripheral blood from patients with asthma. J Allergy Clin Immunol. 2014;134(3):671-678 e4.
Machida K, Aw M, Salter BMA, et al. The role of the TL1A/DR3 Axis in the activation of group 2 innate lymphoid cells in subjects with eosinophilic asthma. Am J Respir Crit Care Med. 2020;202(8):1105-1114.
Matsuyama T, Machida K, Mizuno K, et al. The functional role of group 2 innate lymphoid cells in asthma. Biomolecules. 2023;13(6):893.
Wong CK, Hu S, Cheung PF, Lam CW. Thymic stromal lymphopoietin induces chemotactic and prosurvival effects in eosinophils: implications in allergic inflammation. Am J Respir Cell Mol Biol. 2010;43(3):305-315.
Cook EB, Stahl JL, Schwantes EA, Fox KE, Mathur SK. IL-3 and TNFalpha increase thymic stromal lymphopoietin receptor (TSLPR) expression on eosinophils and enhance TSLP-stimulated degranulation. Clin Mol Allergy. 2012;10(1):8.
Nordenmark L, Hellqvist A, Emson C, et al. Tezepelumab and mucus plugs in patients with moderate-to-severe asthma. NEJM Evid. 2023;2.
Jain N, Llanos-Ackert J, Ambrose C, et al. Efficacy of tezepelumab in patients with severe, uncontrolled asthma and high baseline blood eosinophil counts. Ann Allergy Asthma Immunol. 2022;129(5):S36-S37.
Menzies-Gow AC, Cook J, Kmita B, et al. Efficacy of tezepelumab in patients with severe, uncontrolled asthma, according to baseline blood eosinophil count and allergic status: results from the phase 3 NAVIGATOR study. Allergy. 2021;76:1026.
Allakhverdi Z, Comeau MR, Jessup HK, Delespesse G. Thymic stromal lymphopoietin as a mediator of crosstalk between bronchial smooth muscles and mast cells. J Allergy Clin Immunol. 2009;123(4):958-960 e2.
Kaur D, Doe C, Woodman L, et al. Mast cell-airway smooth muscle crosstalk: the role of thymic stromal lymphopoietin. Chest. 2012;142(1):76-85.
Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID. Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med. 2002;346(22):1699-1705.
Sverrild A, Bergqvist A, Baines KJ, et al. Airway responsiveness to mannitol in asthma is associated with chymase-positive mast cells and eosinophilic airway inflammation. Clin Exp Allergy. 2016;46(2):288-297.
Brightling CE, O'Byrne PM, Porsbjerg C, et al. Effect of tezepelumab on airway hyperresponsiveness by baseline blood eosinophil count in patients with severe, uncontrolled asthma in the phase 2 CASCADE study. Am J Respir Crit Care Med. 2023;207:A4750.
Wu J, Liu F, Zhao J, et al. Thymic stromal lymphopoietin promotes asthmatic airway remodelling in human lung fibroblast cells through STAT3 signalling pathway. Cell Biochem Funct. 2013;31(6):496-503.
Cao L, Liu F, Liu Y, et al. TSLP promotes asthmatic airway remodeling via p38-STAT3 signaling pathway in human lung fibroblast. Exp Lung Res. 2018;44(6):288-301.
Redhu NS, Shan L, Movassagh H, Gounni AS. Thymic stromal lymphopoietin induces migration in human airway smooth muscle cells. Sci Rep. 2013;3:2301.
Cai LM, Zhou YQ, Yang LF, et al. Thymic stromal lymphopoietin induced early stage of epithelial-mesenchymal transition in human bronchial epithelial cells through upregulation of transforming growth factor beta 1. Exp Lung Res. 2019;45(8):221-235.
Denton E, Price DB, Tran TN, et al. Cluster analysis of inflammatory biomarker expression in the international severe asthma registry. J Allergy Clin Immunol Pract. 2021;9(7):2680-2688.e7.
Wechsler ME, Menzies-Gow A, Brightling CE, et al. Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study. Lancet Respir Med. 2022;10(7):650-660.